Kymera Therapeutics, Inc. · NASDAQ:KYMR
Kymera Therapeutics — JDA Annual Meeting 2026
11 slides from Kymera Therapeutics's conference presentation, Jun 12, 2026
Slide 1: KT-621, an Oral, Once Daily STAT6 Degrader: PK, PD, and Safety in Healthy Japanese Adults
June 12, 2026 KT-621, an Oral, Once Daily STAT6 Degrader: Pharmacokinetics, Pharmacodynamics, and Safety in Healthy Japanese Adults Sagar Agarwal, Alice A. McDonald, Evelyn Wang, Heather Paleczny, Nello Mainolfi, Jared Gollob, and Michael B. Feldman Kymera Therapeutics, Inc., Watertown, MA, USA JDA
Slide 2: Targeted Protein Degradation: Achieving Biologics-like Activity With Oral Medicines
Targeted Protein Degradation: Achieving Biologics-like Activity With Oral Medicines Targeted Protein Degradation (TPD) Mechanism of Action Degraders Enable Continuous, Complete Pathway Blockade Harnessing the E3 Ubiquitin Proteasome System Superior to Traditional Small Molecule Inhibitors 1 2 3 4 Sm
Slide 3: STAT6: Highly Validated, Historically Undrugged Target for Type 2 Inflammatory Diseases
STAT6: Highly Validated, Historically Undrugged Target for Treatment of Type 2 Inflammatory Diseases STAT6 KT-621 TRANSCRIPTION FACTOR FIRST-IN-CLASS ORAL, ONCE-DAILY, STAT6 DEGRADER6 • STAT6 is the specific transcription factor in the IL-4/IL-13 pathway1-3 Dupilumab IL-4 Dupilumab IL-4 IL-13 • IL-4
Slide 4: KT-621 Phase 1 Study in Healthy Japanese Adults
KT-621 Phase 1 Study in Healthy Japanese Adults A Phase 1, Randomized, Placebo-Controlled, Multiple-Dose Study of Orally Administered KT-621 in Healthy Japanese Adults Each Cohort Dosed for 7 Days Objectives & Screening Endpoints Cohort 1 Cohort 2 (n=12) (n=12) Baseline entry criteria: Randomized 3:
Slide 5: Demonstrated Linear and Predictable PK
KT-621 Demonstrated Linear and Predictable PK in Healthy Japanese Adults Mean (%CV) Steady-State (Day 7) KT-621 PK Parameters in Japanese and Non-Japanese Adults 250 KT-621 25 mg KT-621 KT-621 KT-621 100 mg 25 mg QD 100 mg QD Mean (±SD) KT-621 Plasma Concentration (ng/mL) 200 Japanese Non-Japanesea
Slide 6: Achieved Rapid, Deep, and Prolonged STAT6 Degradation in Whole Blood of Healthy Japanese Adults
KT-621 Achieved Rapid, Deep, and Prolonged STAT6 Degradation in Whole Blood of Healthy Japanese Adults Percent Change From Baseline in 50 STAT6 Levels Placebo Median Percent Change From KT-621 25 mg QD KT-621 100 mg QD Baseline in STAT6 0 −50 −100 0 hour 8 hour 24 hour Day 4 Day 7 Day 11 Day 21 KT-6
Slide 7: STAT6 Degradation Was Comparable in Healthy Japanese and Non-Japanese Adults
KT-621: STAT6 Degradation Was Comparable in Healthy Japanese and Non-Japanese Adults Japanese Adults Non-Japanese Adultsa Japanese Adults Placebo KT-621 25 mg QD 100 KT-621 100 mg QD From Baseline in STAT6 Median Percent Change Non-Japanese Adults Placebo KT-621 25 mg QD KT-621 100 mg QD 0 −100 D r
Slide 8: KT-621 Was Safe and Well Tolerated in Healthy Japanese Adults
KT-621 Was Safe and Well Tolerated in Healthy Japanese Adults • No serious or severe AEs occurred • No dose-dependent pattern was observed in treatment-emergent AEs (TEAEs) • No TEAEs led to discontinuation • No clinically significant changes in vital signs, laboratory tests, or ECGs were observed f
Slide 9: First Evidence Demonstrating PK, PD, and Safety of a STAT6-Targeted Drug
KT-621: First Evidence Demonstrating PK, PD, and Safety of a STAT6-Targeted Drug in Healthy Japanese Adults • KT-621 demonstrated a favorable PK profile in healthy Japanese adults, with rapid absorption and dose-proportional increases in plasma exposure, comparable to non-Japanese adults • Deep STAT
Slide 10: KT-621: BROADEN2 Phase 2b Trial
KT-621: BROADEN2 Phase 2b Trial Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Dose-ranging Design • Randomized, double-blind, Key Trial Aim placebo-controlled • ~200 patients Establish clinical activity and • Daily dose for 16 weeks; safety in AD to select dose to Adult &
Slide 11: Thank You
Thank You For more information, please visit our Poster #EP6-4 (Abstract #10061) or www.kymeratx.com JDA Annual Meeting | Kyoto | June 11-14, 2026 11